VANCOUVER, British Columbia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)
(the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of
pharmaceutical and nutraceutical products, announced today that it is in the final stages of advanced due diligence for
implementing Blockchain technology for payment processing. The company has been exploring this option for several months and
is working closely with an industry-specific advisory group in designing and implementing a commercialization strategy.
The Company’s online sales platform has seen exponential growth since its launch and with the introduction of a digital currency
payment system, Isodiol anticipates its international footprint will increase significantly. This platform will reduce
processing fees incurred by the Company as well as reduce risks associated with foreign exchange fluctuations.
“There are tremendous benefits to implementing Blockchain technology and we look forward to improving our overall customer
experience by providing alternative payment options,” said Marcos Agramont, CEO of Isodiol International “As Blockchain technology
evolves, Isodiol has every intention to continue improving its payment processing options.”
The Company anticipates providing additional information on this rollout in the coming weeks.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and
nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer
products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive
pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin
care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical
portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and
future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the
expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will
prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking
statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially
from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will
vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as
required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward
looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press
release.
